Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.

Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

In today's session, there are notable price gaps in the US markets on Friday. Take a closer look at the stocks that are gap up and gap down.

While the other companies are testing weight-loss drugs, Allurion has a different approach to obesity.

Allurion Technologies (NYSEALUR) shares are moving higher Friday potentially after after the company announced plans to conduct a clinical study evaluating the combination of its Allurion Program with GLP-1 agonists on Thursday.

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSEALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,240,000 shares of the Company’s common stock at a price of $6.00 per share in a registered direct offering priced at-the-market under NYSE rules.

U.S. stock futures fell on Friday following a 25 basis point rate hike by the Bank of Japan. Futures of all four indices declined.

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSEALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition.

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSEALUR), a company dedicated to ending obesity, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) dated January 15, 2025 for U.S. Patent No. 12,209,677 titled “Binary Fluid Control Valve System”. This patent covers additional claims for an enhanced, next-generation version of Allurion’s proprietary Balloon technology and the introduction of innovative features, particularly to the precision of the valve system that controls balloon opening. The patent is expected to provide protection through July 2039. With the issuance of this patent, the Company now has 20 patents issued in the U.S. and 59 patents issued globally.

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSEALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription agreement with funds affiliated with RTW Investments, LP (“RTW”) for the purchase and sale of 841,751 shares of the Company’s common stock in a private placement at a purchase price of $2.97 per share. The private placement is expected to result in gross proceeds of $2.5 million and extend the Company’s runway through early 2026. The subscription agreement also includes an option to fund up to an additional $10 million in subsequent tranches. The private placement is expected to close on or about January 15, 2025, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the private placement for working capital and other general corporate purposes.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced topline results from the AUDACITY Food & Drug Administration (FDA) pivotal trial evaluating the safety and efficacy of the Allurion Balloon.

Allurion Technologies, Inc. (NYSEALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that its Board of Directors has determined to effect a one-for-twenty five reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced that it received an Acceptance Letter from the Listings Operations Committee of the New York Stock Exchange (the “NYSE”) stating that the NYSE has accepted the Company’s previously submitted plan to regain compliance with the NYSE’s continued listing standard set forth in Section 802.01B of the NYSE’s Listed Company Manual (the “Minimum Market Capitalization Standard”). The Company expects to have until March 1, 2026 to regain compliance with the NYSE’s Minimum Market Capitalization Standard.

Allurion Technologies, Inc. (NYSEALUR), a company dedicated to ending obesity, today announced the launch of AllurionMeds, a unique offering to patients that combines affordable and accessible weight loss medications with the company’s AI-native platform, featuring Coach Iris, to promote long-term weight maintenance, virtual access to dieticians and a connected smart scale measuring not just weight but muscle and bone mass.